Olympic gold medalist gymnast Shawn Johnson East had respiratory syncytial virus-related experiences with all 3 of her ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

There is no vaccine for the common cold. However, there are safe and effective vaccines for the flu and COVID-19.

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Brits are being urged to brace themselves for a 'tripledemic' of Covid, flu, and Respiratory syncytial virus (RSV). And ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

Health officials across Vermont are asking residents to stay safe and prevent the spread of disease by getting updated virus ...

Health experts are warning of a potential 'tripledemic' this winter - here's how to spot the early symptoms of flu, RSV and ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.